• Revenue: Declined 14% versus the prior year.
• Pricing: Down 9%, with over half of the decline due to adjustments in certain cost-plus contracts.
• FX Headwind: 4% impact on revenue growth, largely driven by the Brazilian real and European currencies.
• Volume: Down 1% versus the prior year, with growth in Latin America offsetting declines elsewhere.
• North America Sales: Declined 28% due to lower volume and cautious ordering by retailers and growers.
• Latin America Sales: Grew 17%, excluding FX headwinds.
• Asia Sales: Declined 21%, excluding currency impacts.
• EMEA Sales: Declined 7%, excluding currency impacts.
• EBITDA: Declined 25% due to lower price, FX headwinds, and reduced volume.
• Interest Expense: $50.1 million, down over $11 million compared to the prior year period.
• Effective Tax Rate: 14% in the first quarter.
• Gross Debt: Approximately $4 billion, up $640 million from the prior quarter.
• Net Debt: Approximately $3.7 billion.
• Free Cash Flow: Negative $596 million, $408 million lower than the prior year period.
• Full-Year Guidance: Sales expected to be flat, adjusted EBITDA to grow 1%, and adjusted earnings per share to be flat at the midpoint.

• Warning! GuruFocus has detected 6 Warning Signs with FMC.

Release Date: May 01, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• FMC Corp (NYSE:FMC) has made strong progress in reducing channel inventory levels, particularly in regions outside Asia, positioning the company well for the second half of the year.
• The company has successfully implemented its Rynaxypyr strategy, offering both lower-priced solo formulations and higher-value patented mixtures, which is expected to drive sales growth.
• FMC Corp (NYSE:FMC) has established a new route to market in Brazil, selling directly to large corn and soybean growers, which is anticipated to provide a significant growth opportunity.
• The company's growth portfolio, including new active ingredients like fluindapyr and Isoflex, is well-positioned to deliver strong results, with recent product registrations supporting future sales.
• FMC Corp (NYSE:FMC) has demonstrated resilience against tariff impacts by leveraging supply chain flexibility and cost-saving measures, minimizing the financial impact on the company.

Negative Points

• FMC Corp (NYSE:FMC) experienced a 14% decline in sales in Q1 compared to the previous year, driven by lower pricing and FX headwinds.
• The company faced a 25% decline in EBITDA in Q1 due to lower prices, FX headwinds, and reduced volume.
• North American sales declined by 28% due to cautious purchasing behavior from retailers and growers, impacting overall performance.
• The company anticipates a $15 million to $20 million cost headwind from tariffs, which could affect profitability if not managed effectively.
• FMC Corp (NYSE:FMC) continues to face challenges in Asia and EMEA, with sales declines due to prudent selling strategies and loss of product registrations.

Q & A Highlights

Q: Can you describe the price trends in the crop production market outside of diamide? Has the pricing bottomed? What would you expect from price going forward this year? A: Pierre Brondeau, Chairman and CEO, explained that FMC's pricing in Q1 was in the high single digits, influenced by lower pricing to diamide partners and a competitive market in Brazil. He expects pricing comparisons to ease in the second half of the year due to more stable conditions and easier year-on-year comparisons.

Q: Can you give guidance on why you expect strong growth in the second half of the year? A: Pierre Brondeau expressed high confidence in H2 growth, driven by strong demand for new products like fluindapyr and Isoflex, a new route to market in Brazil, and a healthier channel inventory situation. He also mentioned a $50 million automatic growth at the EBITDA level due to the absence of negative impacts from 2024.

Q: How are you offsetting the $15 million to $20 million tariff headwind? A: Pierre Brondeau stated that the cost savings actions were not specifically due to tariffs but were part of their ongoing plans. The company is focusing on creating demand from growers to pull products from retailers, which helps manage channel inventory and supports growth.

Q: Does reducing channel inventories involve giving significant rebates or discounts to customers? A: Pierre Brondeau clarified that FMC shifted its focus to promoting products directly to growers, creating demand without needing to offer rebates or discounts. This strategy helps manage inventory levels without financial incentives.

Q: Can you talk about the diamide strategy and your confidence in growth post-patent? A: Pierre Brondeau explained that FMC is lowering manufacturing costs to compete with generics and is introducing new products to maintain and grow market share. The strategy aims to protect current earnings from Rynaxypyr while introducing new formulations to address resistance and expand market reach.

Q: What are the alternatives for sourcing raw materials impacted by tariffs? A: Andrew Sandifer, CFO, highlighted FMC's flexible supply chain with multiple sources for critical raw materials. The company is prepared to adjust sourcing and pricing strategies as tariffs evolve, aiming to minimize impacts through exemptions, duty drawbacks, and potential price adjustments.

Q: Can you share more about customer order patterns, especially in North America? A: Pierre Brondeau noted that customers were buying closer to planting time, leading to slower order patterns in Q1. However, demand is picking up in Q2, with a faster speed of purchase observed in Europe, indicating a positive trend.

Q: How does selling directly to farmers compare to selling through the channel? A: Pierre Brondeau and Ronaldo Pereira explained that the net contribution is similar whether selling directly or through the channel. Direct sales require dedicated personnel but offer similar terms and profitability, with no significant difference in cash conversion.

Q: Can you explain the second half EBITDA bridge and the impact of price and FX? A: Andrew Sandifer stated that the price and FX headwinds are interconnected, especially in European markets. The second half is expected to have a lower price headwind than the first half, with FX impacts dropping through more heavily than historical averages.

Q: How will the new route to market in Brazil impact results? A: Pierre Brondeau and Ronaldo Pereira expressed confidence in the new route to market in Brazil, which is expected to become positive in Q3. The organization is in place, and new technologies are driving demand, positioning FMC for growth in the second half of 2025.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.